Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 5 of 6

Economic information and modeling report

68 evidence topics · 28 sources

Modeling overview

Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.

Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec

No evidence found.

ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab

Budget impact model

Approach and framework

Budget impact model of cretostimogene grenadenorepvec: approach and framework

No evidence found.

Model structures of published cost-effectiveness and cost-per-responder analyses

Perspective and time frame

Budget impact model of cretostimogene grenadenorepvec: perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

Budget impact model of cretostimogene grenadenorepvec: eligible population inputs

No evidence found.

Eligible population inputs in a published budget impact model

“In the base-case analysis, the model considered adults (aged ≥18 years) with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1. Prevalent cases were considered in Year 1 and incident cases were considered in Years 2–3.” (opens the source at this quote in a new tab)

“Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data” (opens the source at this quote in a new tab)

“a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only” (opens the source at this quote in a new tab)

“Among patients with high-risk NMIBC, 56.5% were treated with BCG” (opens the source at this quote in a new tab)

“and 30% of those were unresponsive to BCG” (opens the source at this quote in a new tab)

“Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data” (opens the source at this quote in a new tab)

“An annual recurrence rate of 55.1% was used” (opens the source at this quote in a new tab)

Cost assumptions

Budget impact model of cretostimogene grenadenorepvec: cost assumptions

No evidence found.

Cretostimogene grenadenorepvec price

No evidence found.

Gemcitabine intravesical system wholesale acquisition cost

No evidence found.

Medicare Part B payment limits for comparator agents, fourth quarter of 2026
HCPCS code and productShort descriptionHCPCS code dosagePayment limit (USD)Coinsurance percentage
J9029 nadofaragene firadenovec (Adstiladrin)“Instill adstiladrin, tx dose”“PER THERAPEUTIC DOSE”“65200.563”“20.000”
J9028 nogapendekin alfa inbakicept (Anktiva)“Inj, nogapendekin pmln, 1mcg”“1 MCG”“94.139”“20.000”
J9183 gemcitabine intravesical system (Inlexzo)“Gemcitabine intravesical sys”“225 MG”“73054.053”“20.000”
J9271 pembrolizumab (Keytruda)“Inj pembrolizumab”“1 MG”“62.253”“20.000”
J9030 BCG live intravesical“Bcg live intravesical 1mg”“1 MG”“3.532”“20.000”
J9357 valrubicin“Valrubicin injection”“200 MG”“1230.664”“20.000”
J9201 gemcitabine“In gemcitabine hcl nos 200mg”“200 MG”“2.734”“20.000”
J9171 docetaxel“Docetaxel injection”“1 MG”“0.471”“20.000”
J9280 mitomycin“Mitomycin injection”“5 MG”“34.838”“20.000”
Three-month Medicare costs in a published cost-effectiveness model, 2024
Item3 month cost (USD)Range
Radical cystectomy without complications“15850”View highlighted excerpt for this quote“14439–16472”View highlighted excerpt for this quote
Radical cystectomy with major complications“37330”View highlighted excerpt for this quote“36275–37952”View highlighted excerpt for this quote
Pembrolizumab, 200 mg every 3 weeks“46356”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Gemcitabine-docetaxel induction“828”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Gemcitabine-docetaxel maintenance“414”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nadofaragene, 75 mL every 3 months“63594”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nogapendekin alfa inbakicept-BCG induction“216189”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nogapendekin alfa inbakicept-BCG maintenance“108095”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Recurrence, initial cost (TURBT, office visit)“3779”View highlighted excerpt for this quote“2070–5539”View highlighted excerpt for this quote
Surveillance on bladder-sparing therapy“3638 per year”View highlighted excerpt for this quote“3384–7284”View highlighted excerpt for this quote

Model outcomes

Budget impact model of cretostimogene grenadenorepvec: model outcomes

No evidence found.

Health-state utility values used in a published cost-effectiveness model

Results

Base case
Budget impact model of cretostimogene grenadenorepvec: base-case results

No evidence found.

Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years
Index patient and strategyCost (5-year USD)Effectiveness (5-year QALY)ICER (USD/QALY)Net monetary benefit
Index patient 1: gemcitabine/docetaxel“78,539”View highlighted excerpt for this quote“3.95”View highlighted excerpt for this quote“Ref.”View highlighted excerpt for this quote“316,053”View highlighted excerpt for this quote
Index patient 1: radical cystectomy“96,909”View highlighted excerpt for this quote“3.78”View highlighted excerpt for this quote“−109.912”View highlighted excerpt for this quote“280,971”View highlighted excerpt for this quote
Index patient 1: pembrolizumab“226,879”View highlighted excerpt for this quote“3.82”View highlighted excerpt for this quote“−1,137,869”View highlighted excerpt for this quote“154,677”View highlighted excerpt for this quote
Index patient 1: nadofaragene“296,318”View highlighted excerpt for this quote“3.84”View highlighted excerpt for this quote“−2,154,264”View highlighted excerpt for this quote“88,165”View highlighted excerpt for this quote
Index patient 1: NAI-BCG“529,801”View highlighted excerpt for this quote“3.85”View highlighted excerpt for this quote“−4,685,203”View highlighted excerpt for this quote“−144,840”View highlighted excerpt for this quote
Index patient 3: pembrolizumab“419,022”View highlighted excerpt for this quote“3.88”View highlighted excerpt for this quote“Ref.”View highlighted excerpt for this quote“−31,083”View highlighted excerpt for this quote
Index patient 3: nadofaragene“449,307”View highlighted excerpt for this quote“3.90”View highlighted excerpt for this quote“1,469,775”View highlighted excerpt for this quote“−59,307”View highlighted excerpt for this quote
Index patient 3: NAI-BCG“704,172”View highlighted excerpt for this quote“3.83”View highlighted excerpt for this quote“−3,847,835”View highlighted excerpt for this quote“−320.796”View highlighted excerpt for this quote
Scenario analyses
Budget impact model of cretostimogene grenadenorepvec: scenario analyses

No evidence found.

Budget impact model discussion

Summary

Task force good-practice guidance lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker and presentation as a series of scenario analyses. For cretostimogene grenadenorepvec, two of these inputs are not yet available: a price, and a labeled population and dosing schedule. CG Oncology expects to complete its BLA “before the end of March 2027” and, after FDA feedback, plans to include high-grade papillary-only disease alongside CIS with or without papillary tumors.

The eligible population depends on which BCG-unresponsive disease is included. CG Oncology estimates up to 25,000 addressable patients with BCG-unresponsive NMIBC from internal research. In the nadofaragene firadenovec budget impact model of one million members, 5.5 adults with CIS ± Ta/T1 disease were eligible in Year 1, against 33.2 when papillary-only disease was added; that model applied 56.5% BCG treatment and 30% BCG unresponsiveness. The 2020 ICER review assumed 38% BCG non-response and derived 70,135 prevalent eligible individuals, of whom 18,956 (27%) had CIS. The authors of that model state that up to 80% of patients decline or are ineligible for cystectomy.

On costs, the Form 10-K describes cretostimogene as a six-week induction course, with three weekly maintenance doses every three months for the first 12 months and every six months for the next 24 months. Comparator list prices are $62,740.70 per Adstiladrin box (“4 vials x 20 ml”; instilled once every three months; October 2026), $35,800.00 per 400 mcg Anktiva vial (January 2025), and $25,034.88 per pembrolizumab dose given every 6 weeks (September 2026); no wholesale acquisition cost was found for the gemcitabine intravesical system, whose fourth-quarter 2026 Medicare Part B payment limit is $73,054.053 per 225 mg system. Each intravesical instillation also carries administration and surveillance costs (CPT 51720, 52000, 88112), and in the nadofaragene firadenovec model increased drug and administration costs were partially offset by savings from reduced progression, fewer cystectomies, and lower adverse event rates. In the published models, results were most influenced by uptake rate, drug cost, and target population size in the budget impact model, and the 5-year Markov model was sensitive to cost alone in one-way sensitivity analysis. The budget impact model and the cost-per-responder model were funded by Ferring Pharmaceuticals and Johnson & Johnson, and the nogapendekin alfa inbakicept analysis is a preliminary report from ImmunityBio.